Management of Pediatric Chronic Spontaneous Urticaria
Abstract
Chronic urticaria (CU) occurs when pruritic wheals and/or angioedema manifests on most days of the week and persists for at least 6 weeks. Recent evidence suggests that the point prevalence of pediatric CU is similar to adults, affecting ~ 0.5%-1.5% of children, with no sex predilection. While ~ 20% of CU cases have an underlying physical/inducible trigger (chronic inducible urticaria, CIndU), in most cases the hives occur spontaneously (chronic spontaneous urticaria, CSU).
References
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and Angioedema Across the Ages. J Allergy Clin Immunol Pract. 2020;8(6):1866-1874.
Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423-432.
Goldstein S, Gabriel S, Kianifard F, Ortiz B, Skoner DP. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500-504.
Curto Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol. 2019;29(6):627-635.
Netchiporouk E, Sasseville D, Moreau L, Habel Y, Rahme E, Ben-Shoshan M. Evaluating Comorbidities, Natural History, and Predictors of Early Resolution in a Cohort of Children With Chronic Urticaria. JAMA Dermatol. 2017;153(12):1236-1242.
Fernando S, Broadfoot A. Chronic urticaria–assessment and treatment. Australian family physician. 2010;39(3):135-138.
Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277.
Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440-1460.
Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019;10:627.
Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876-882.
Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017 Jun;139(6):1772-1781.e1.
Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705-712.
Altrichter S, Zampeli V, Ellrich A, Zhang K, Church MK, Maurer M. IgM and IgA in addition to IgG autoantibodies against FcεRIа are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020.
Tondury B, Muehleisen B, Ballmer-Weber BK, et al. The Pictorial Representation of Illness and Self Measure (PRISM) instrument reveals a high burden of suffering in patients with chronic urticaria. J Investig Allergol Clin Immunol. 2011;21(2):93-100.
Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J Investig Allergol Clin Immunol. 2009;19(Suppl 2):21-26.
Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score-Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1181.
Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372.e1361-1366.
Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093-1101.
Williams PV. Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice. Paediatr Drugs. 2020;22(1):21-28.
Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2-12.
Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431-1444.
Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466.
Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139-1150.e1134.
Kalpaklioglu F, Baccioglu A. Efficacy and safety of H1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem. 2012;11(3):230-237.
Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437-464.
Fitzsimons R, Van Der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122-131.
Bolognia J, Schaffer JV, Cerroni L. Dermatology. 2018.
Palmer RB, Reynolds KM, Banner W, et al. Adverse events associated with diphenhydramine in children, 2008-2015. Clin Toxicol (Phila). 2020;58(2):99-106.
De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56-60.
Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(9):145-155.
Yanai K, Yoshikawa T, Yanai A, et al. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther. 2017;178:148-156.
Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H(1) receptor. Eur J Pharmacol. 2018;838:107-111.
Wolverton SE. Comprehensive Dermatologic Drug Therapy: Expert Consult – Online and Print. Elsevier Health Sciences. 2012.
La Rosa M, Leonardi S, Marchese G, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol. 2001;87(1):48-53.
Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol. 2016;27(1):55-61.
Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48(4):535-541.
Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40(1):72-76.
Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662-669.
Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010;31(4):290-295.
Novak Z, Yanez A, Kiss I, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatric Allergy and Immunology. 2016;27(5):493-498.
Hide M, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial. Allergol Int. 2019;68(1):59-67.
Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007;62(5):539-546.
Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517-522.
Gabrielli S, Le M, Netchiporouk E, et al. Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines. J Am Acad Dermatol. 2020;82(6):1535-1537.
Gabrielli S, Le M, Netchiporouk E, et al. Reply to “Comment on: ‘Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines’”. J Am Acad Dermatol. 2020;83(5):e365-e366.
Inc. NPC. Product Monograph – XOLAIR® (Omalizumab). https://www.novartis.ca/sites/www.novartis.ca/files/xolair_scrip_e.pdf. Published 2015. Accessed March 22, 2020.
Netchiporouk E, Nguyen CH, Thuraisingham T, Jafarian F, Maurer M, Ben-Shoshan M. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585-588.
Poddighe D, Vangelista L. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria. Cell Immunol. 2020;358:104215.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
Saini SS, Bindslev Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75.
Asero R, Casalone R, Iemoli E. Extraordinary response to omalizumab in a child with severe chronic urticaria. Eur Ann Allergy Clin Immunol. 2014;46(1):41-42.
Parisi GF, Papale M, Tardino LG, et al. Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria. J Dermatolog Treat. 2018;29(sup4):10-11.
Porcaro F, Di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. Pediatr Pulmonol. 2017;52(5):E26-e28.
Uysal P, Erge D. Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab. Turk Pediatri Ars. 2018;53(4):250-254.
Staubach P, Peveling-Oberhag A, Lang BM, Zimmer S, Sohn A, Mann C. Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review. J Dermatolog Treat. 2020;1-4.
Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series. Pediatr Dermatol. 2020;37(6):1051-1054.
Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature. Dermatol Ther. 2020;33(4):e13489.
Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Ann Allergy Asthma Immunol. 2019;123(2):208-210.e202.
Sirufo MM, Ginaldi L, De Martinis M. Successful Treatment With Omalizumab in a Child With Asthma and Urticaria: A Clinical Case Report. Front Pediatr. 2019;7:213.
Jesenak M, Ciljakova M, Janickova M, Banovcin P. Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria. J Investig Allergol Clin Immunol. 2019;29(2):144-146.
Ossorio-García L, Jiménez-Gallo D, Albarrán-Planelles C, Arjona-Aguilera C, Linares-Barrios M. Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab. Clin Exp Dermatol. 2016;41(8):929-930.
Leonardi L, Uva A, Duse M. Chronic urticaria in a child affected by atopic dermatitis: effective treatment with omalizumab. J Dermatolog Treat. 2018;29(sup3):17-19.
Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-125.
Harrison CA, Bastan R, Peirce MJ, Munday MR, Peachell PT. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. British Journal of Pharmacology. 2007;150(4):509-518.
Grattan CEH, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. British Journal of Dermatology. 2000;143(2):365-372.
Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clinical & Experimental Allergy. 2005;35(5):554-559.
Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409-413.
Giuliodori K, Ganzetti G, Campanati A, Simonetti O, Marconi B, Offidani A. A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin. J Eur Acad Dermatol Venereol. 2009;23(5):619-620.
Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract. 2014;2(4):434-438.
Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386-390.
Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A. Corticosteroid-related toxicity in patients with chronic idiopathic urticariachronic spontaneous urticaria. Allergy Asthma Proc. 2016;37(6):458-465.
Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression–inhibitory effects ofanti-inflammatory drugs. J Allergy Clin Immunol. 2000;105(3):552-560.
Bisgaard H. Vascular effects of leukotriene D4 in human skin. J Invest Dermatol. 1987;88(2):109-114.
Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004 Jan;113(1):134-40.
Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568-579.
Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014;8:839-850.
Di Lorenzo G, Pacor ML, Mansueto P, et al. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol. 2006;31(3):327-334.
McBayne TO, Siddall OM. Montelukast treatment of urticaria. Ann Pharmacother. 2006;40(5):939-942.
De Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24.
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166.
Costedoat-Chalumeau N, Dunogué B, Leroux G, et al. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. Clin Rev Allergy Immunol. 2015;49(3):317-326.
Lebin JA, LeSaint KT. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management. West J Emerg Med. 2020;21(4):760-763.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394.
Boonpiyathad T, Sangasapaviliya A. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. Eur Ann Allergy Clin Immunol. 2017;49(5):220-224.
Iweala OI, Copenhaver C, Wu EY, Moran TP. Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria. Ann Allergy Asthma Immunol. 2018;120(1):102-104.
Oguz Topal I, Kocaturk E, Gungor S, Durmuscan M, Sucu V, Yıldırmak S. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? J Dermatolog Treat. 2016;27(2):163-6.
Yuan I, Katari P, Shaker M. Vitamin D treatment for chronic urticaria: a case report. J Med Case Rep. 2019;13(1):193.
Vogiatzi MG, Jacobson-Dickman E, DeBoer MD, Drugs, Therapeutics Committee of The Pediatric Endocrine S. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014;99(4):1132-1141.
Khafagy NH, Salem SA, Ghaly EG. Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria. Photodermatol Photoimmunol Photomed. 2013;29(1):12-17.
Shi CR, Li YP, Luo YJ, et al. IgE-mediated allergy: a rare cause of chronic spontaneous urticarial with allergen-specific immunotherapy as treatment option – a systematic review with meta-analysis from China. J Eur Acad Dermatol Venereol. 2012;26(5):533-544.
